Asset Details
Do you wish to reserve the book?
PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
Do you wish to request the book?
PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
2022
Overview
Cancer immunotherapy, especially immune-checkpoint inhibitors (ICIs), has paved a new way for the treatment of many types of malignancies, particularly advanced-stage cancers. Accumulating evidence suggests that as a molecular imaging modality, positron emission tomography/computed tomography (PET/CT) can play a vital role in the management of ICIs therapy by using different molecular probes and metabolic parameters. In this review, we will provide a comprehensive overview of the clinical data to support the importance of 18 F-fluorodeoxyglucose PET/CT ( 18 F-FDG PET/CT) imaging in the treatment of ICIs, including the evaluation of the tumor microenvironment, discovery of immune-related adverse events, evaluation of therapeutic efficacy, and prediction of therapeutic prognosis. We also discuss perspectives on the development direction of 18 F-FDG PET/CT imaging, with a particular emphasis on possible challenges in the future. In addition, we summarize the researches on novel PET molecular probes that are expected to potentially promote the precise application of ICIs.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Cells
/ Glucose
/ Humans
/ Hypoxia
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - therapeutic use
/ immune-checkpoint inhibitors (ICIs)
/ Neoplasms - diagnostic imaging
/ Positron emission tomography
/ Positron Emission Tomography Computed Tomography - methods
/ positron emission tomography/computed tomography (PET/CT)
/ Probes
